Neurodegenerative Diseases Pathology

Protein Misfolding and Aggregation

• Abnormal protein conformations misfold and adopt beta-pleated sheet structures, resisting normal degradation
• Prion-like propagation: Misfolded proteins recruit normal protein molecules, triggering conformational changes that spread pathology cell-to-cell and brain region-to-region
• Different diseases feature characteristic proteins: amyloid-beta (Aβ) and tau in Alzheimer disease; alpha-synuclein in Parkinson disease; polyglutamine expansions in Huntington disease; SOD1, FUS, and TDP-43 in ALS
• Aggregates form intracellular inclusions (Lewy bodies, neurofibrillary tangles, Pick bodies) that disrupt cellular function and trigger neuronal death

Excitotoxicity and Calcium Dysregulation

• Glutamate excitotoxicity causes excessive activation of NMDA and AMPA receptors, leading to uncontrolled Ca²⁺ influx
• Mitochondrial calcium overload impairs oxidative phosphorylation, generating reactive oxygen species (ROS) and depleting ATP
• Energy failure triggers excitotoxic neuronal death through apoptotic and necrotic pathways
• Particularly important in motor neuron diseases where glutamate transporter dysfunction contributes to pathogenesis

Mitochondrial Dysfunction and Oxidative Stress

• Impaired oxidative phosphorylation reduces ATP production and increases ROS generation
• ROS damage cellular macromolecules (proteins, lipids, DNA) through oxidative modification
• Mitochondrial DNA mutations contribute to energy failure, particularly in hereditary forms
• Oxidative stress triggers lipid peroxidation in myelin sheaths and neuronal membranes, causing structural collapse
• Creates a self-perpetuating cycle: protein aggregates impair mitochondria → ROS generation → increased protein misfolding

Neuroinflammation and Glial Activation

• Microglial activation releases pro-inflammatory cytokines (TNF-α, IL-1β, IL-6) and complement proteins
• Astrocytic activation produces neurotoxic mediators and reduces growth factor support
• Complement cascade activation (classical and alternative pathways) contributes to neuronal destruction
• Chronic neuroinflammation perpetuates neurodegeneration independent of initial trigger
• Neuroinflammatory markers (phosphorylated tau, inflammatory cytokines) correlate with disease severity

Impaired Protein Degradation Pathways

• Proteasomal dysfunction: 26S proteasome fails to degrade misfolded proteins efficiently
• Autophagy-lysosomal pathway impairment: Reduced autophagy flux prevents clearance of protein aggregates and dysfunctional organelles
• Chaperone dysfunction: Heat shock proteins (HSP70, HSP90) fail to refold or facilitate degradation of misfolded proteins
• Accumulation of ubiquitinated protein inclusions indicates impaired protein quality control
• Both pathways are saturated by excessive misfolded protein burden

Synaptic Dysfunction and Disconnection

• Progressive loss of dendritic spines and synaptic terminals precedes frank neuronal death
• Presynaptic protein dysfunction impairs neurotransmitter synthesis, packaging, and release
• Postsynaptic receptor dysfunction reduces neurotransmitter responsiveness
• Synaptic disconnection hypothesis: Cognitive and motor decline correlates better with synapse loss than neuronal loss
• Establishes early neurological symptoms despite incomplete neuronal death

Axonal Transport Defects

• Impaired anterograde transport (toward axon terminal) reduces delivery of trophic factors and synaptic proteins
• Retrograde transport dysfunction impairs neuronal feedback and removal of toxic materials
• Mediated by kinesin and dynein motor proteins; frequently disrupted by protein aggregates
• Results in distal axonopathy: Progressive degeneration beginning at axon terminals and advancing proximally
• Characteristic pattern in motor neuron diseases (length-dependent degeneration)

Genetic Factors

• Monogenic inheritance patterns (autosomal dominant, autosomal recessive, X-linked):
• Huntington disease: CAG trinucleotide repeat expansion (HTT gene)
• Familial Alzheimer disease: PSEN1, PSEN2, APP mutations
• Familial ALS: SOD1, C9orf72, FUS, TARDBP mutations
• Hereditary spastic paraplegia: SPG genes
• Polyglottic genetic architecture in sporadic cases with multiple susceptibility loci
• APOE4 allele: Strong genetic risk factor for late-onset Alzheimer disease (dose-dependent effect)
• Gene penetrance highly variable; incomplete penetrance observed in some monogenic forms

Age-Related Factors

• Advancing age is the strongest risk factor for most neurodegenerative diseases
• Age-related decline in proteostasis capacity: Reduced proteasomal and autophagic efficiency
• Accumulation of cellular damage over decades (oxidative stress, mtDNA mutations)
• Progressive telomere shortening in neurons; impaired DNA repair mechanisms
• Reduced trophic factor signaling and neuroplasticity with aging

Environmental Exposures

• Parkinsonism-dementia complex of Guam: Cycad seed consumption (β-methylamino-L-alanine toxin)
• Paraquat and rotenone: Pesticide exposure associated with increased Parkinson disease risk
• Heavy metals (lead, mercury, manganese): Cumulative neurotoxic burden
• Head trauma: Repetitive traumatic brain injury increases risk for chronic traumatic encephalopathy and parkinsonian syndromes
• Occupational exposures: Welding fumes (manganese), organic solvents

Metabolic and Systemic Factors

• Diabetes and metabolic syndrome: Increased glycation of proteins; impaired glucose metabolism in brain
• Cardiovascular disease and hypertension: Reduced cerebral perfusion; vascular contributions to dementia
• Obesity: Systemic inflammatory state; altered metabolic signaling
• Sleep disorders: Impaired clearance of toxic proteins during slow-wave sleep (glymphatic dysfunction)
• Chronic neuroinflammation: From peripheral infections, systemic inflammation

Lifestyle Factors

• Physical inactivity: Reduced neuroplasticity, trophic factor signaling, and cognitive reserve
• Cognitive inactivity: Reduced recruitment of neural networks; accelerated cognitive decline
• Social isolation: Loss of cognitive stimulation and psychosocial stress
• Sleep deprivation: Impaired protein clearance and glymphatic function
• Poor diet: Inadequate antioxidants, B vitamins, omega-3 fatty acids

Parkinson Disease

• Bradykinesia: Slowing of voluntary movements reflecting substantia nigra dopaminergic neuron loss
• Resting tremor (4-6 Hz "pill-rolling"): Due to imbalance between dopaminergic and cholinergic systems
• Rigidity: Increased muscle tone throughout range of motion ("cogwheel" rigidity)
• Postural instability and gait disturbance: Loss of postural reflexes; characteristic "festinating gait" (accelerating forward propulsion)
• Non-motor features: Depression, anxiety, sleep disorders, hyposmia, constipation, orthostatic hypotension
• Morphological correlate: Marked loss of pigmented dopaminergic neurons in substantia nigra pars compacta; depigmentation visible on gross inspection

Alzheimer Disease

• Insidious memory loss: Initially affecting short-term memory; due to neocortical and hippocampal neuronal loss
• Cognitive decline (language, visuospatial, executive function): Progressive and irreversible
• Behavioral changes: Apathy, depression, irritability, agitation
• Apraxia and agnosia: Loss of object recognition and motor planning ability
• Advanced stage: Mutism, loss of purposeful movement, incontinence, unresponsiveness
• Morphological correlates: Cortical atrophy (particularly temporal and parietal lobes); ventricular enlargement; hippocampal atrophy

Huntington Disease

• Involuntary movements (chorea): Jerky, irregular, purposeless movements affecting face, trunk, limbs; due to caudate nucleus neuronal loss
• Personality changes and psychiatric symptoms: Depression, obsessive-compulsive behaviors, psychosis
• Cognitive decline: Bradykinesia and apathy dominate; memory relatively preserved early
• Motor abnormalities: Dystonia, rigidity, postural instability; eventually progressing to akinetic-rigid state
• Gait abnormality: Characteristic "dancing" gait with irregular, hypometric movements
• Morphological correlates: Selective caudate atrophy producing "box-like" appearance of lateral ventricles; severe striatal neurodegeneration

Amyotrophic Lateral Sclerosis (ALS)

• Asymmetric weakness: Distal lower extremity initially in ~50% of patients; upper extremity or bulbar in others; reflects motor neuron loss
• Fasciculations: Spontaneous, visible muscle twitches indicating active denervation
• Spasticity: Hyperreflexia and upper motor neuron signs (Babinski sign) from corticospinal tract degeneration
• Bulbar involvement: Dysarthria, dysphagia, emotional lability (pseudobulbar affect)
• Respiratory insufficiency: Progressive dyspnea from diaphragmatic paralysis; eventual respiratory failure
• Preserved cognition: Most patients maintain intellectual function until terminal stages
• Morphological correlates: Loss of motor neurons in anterior horn of spinal cord; corticospinal tract degeneration; motor cortex neuronal loss

Frontotemporal Dementia

• Behavioral variant: Disinhibition, impulsivity, inappropriate behavior; apathy and loss of empathy; orbitalfrontal and medial prefrontal cortex atrophy
• Non-fluent aphasia variant: Effortful speech, agrammatism, anomia; relative sparing of comprehension; left inferior frontal atrophy
• Semantic dementia variant: Fluent but empty speech; progressive loss of word meaning and object knowledge; bilateral anterior temporal lobe atrophy
• Personality change: Often presents as first symptom, preceding cognitive decline
• Motor features: May develop parkinsonism or ALS-like features with disease progression
• Relative preservation of memory: Distinguishes from Alzheimer disease

Lewy Body Dementia

• Cognitive fluctuations: Minute-to-minute variability in alertness and attention; key distinguishing feature
• Visual hallucinations: Complex, detailed images (animals, people) occurring early and frequently
• Parkinsonism: Often asymmetric; may precede cognitive symptoms ("Parkinson disease dementia") or occur simultaneously
• REM sleep behavior disorder: Acting out dreams; often precedes other symptoms by years
• Neuroleptic sensitivity: Severe adverse reactions to antipsychotics; life-threatening
• Morphological correlates: Lewy bodies throughout cortex and brainstem; less prominent amyloid and tau pathology than Alzheimer disease

Histological Findings

Alzheimer Disease

• Amyloid plaques (Aβ deposits): Extracellular deposits of amyloid-beta-42 in core surrounded by dystrophic neurites; stain with Congo red showing apple-green birefringence under polarized light
• Neurofibrillary tangles (NFTs): Hyperphosphorylated tau protein forming intracellular twisted filaments within neuronal soma and axons; detected with phospho-tau antibodies and Gallyas silver stains
• Neuritic plaques: Dystrophic axons and dendrites surrounding amyloid cores, containing tau and ubiquitin
• Cerebellar amyloid angiopathy: Aβ deposition in blood vessel walls causing vessel wall weakness and microhemorrhages
• Neuronal loss and gliosis: Particularly in hippocampus, entorhinal cortex, and temporal neocortex
• Granulovacuolar degeneration and Hirano bodies: Inclusions within hippocampal neurons; markers of neuronal stress

Parkinson Disease

• Lewy bodies: Alpha-synuclein-immunopositive intracytoplasmic inclusions with concentric laminated structure; hyaline core surrounded by radiating filaments
• Lewy neurites: Alpha-synuclein-positive pathological processes (axons, dendrites) without forming compact inclusions
• Neuronal loss: Marked loss of pigmented neurons in substantia nigra pars compacta (SNc); estimated 50-70% loss at diagnosis
• Depigmentation: Gross appearance of SNc transitions from dark brown (from neuromelanin) to pale gray-tan
• Gliosis: Astrocytic and microglial proliferation in affected regions
• Brainstem-predominant pathology: Earliest and most severe involvement of SNc, followed by locus coeruleus

Huntington Disease

• Neuronal intranuclear inclusions (NII) and cytoplasmic inclusions: Polyglutamine-expanded huntingtin protein aggregates; stain with ubiquitin and polyglutamine antibodies
• Selective neuronal loss: Severe degeneration of medium spiny neurons (GABAergic) in dorsolateral striatum
• Preservation of large aspiny neurons: Creates marked selectivity of neuronal vulnerability
• Gross appearance: Severe caudate and putamen atrophy; striatum appears shrunken with loss of gray matter volume
• Cortical atrophy: Secondary cortical involvement in advanced disease
• Gliosis: Reactive astrocytosis in affected striatum

Amyotrophic Lateral Sclerosis

• Motor neuron loss: Progressive degeneration of lower motor neurons (anterior horn) and upper motor neurons (motor cortex layer V)
• TDP-43 pathology: Phosphorylated TDP-43 (TAR DNA-binding protein 43) accumulation in motor neurons; forms cytoplasmic inclusions; present in ~97% of ALS cases
• SOD1 inclusions: In SOD1-mutant ALS; polyubiquitinated SOD1 protein aggregates
• Denervation and reinnervation: Muscle shows grouped atrophy from denervation; scattered large fibers from attempted reinnervation by remaining motor neurons
• Degeneration of corticospinal tracts: Loss of myelinated axons in lateral funiculus of spinal cord; astrocytic gliosis
• Axonal spheroids: Swollen axon terminals containing accumulated neurofilament proteins

Lewy Body Dementia

• Lewy bodies: Widespread cortical distribution (unlike Parkinson disease with brainstem predominance); alpha-synuclein-positive
• Cortical Lewy bodies: Found within neurons throughout cerebral cortex, particularly cingulate, entorhinal, and temporal cortex
• Amyloid plaques and tau pathology: Often present but less extensive than in Alzheimer disease
• Neuronal loss: Particularly in anterior cingulate and entorhinal cortex
• Preserved substantia nigra: Less severe nigral degeneration than in Parkinson disease

Frontotemporal Dementia

• Tau pathology (Pick disease type): Pick bodies = **rounded intracytoplasmic tau inclusions

Immediate stabilisation

• Airway and respiratory failure: in ALS, hypoventilation from diaphragmatic denervation is the proximate cause of death; the American Academy of Neurology (AAN) practice parameter supports early non-invasive positive-pressure ventilation when forced vital capacity falls or orthostatic dyspnea/orthopnea appears, and percutaneous gastrostomy before respiratory reserve is lost.
• Aspiration and delirium in any advanced dementia require swallow evaluation and a search for reversible triggers (infection, drugs, metabolic derangement) before symptom-directed therapy.

First-line disease-specific therapy

• Parkinson disease — dopamine replacement: levodopa/carbidopa is the most effective symptomatic agent (AAN guidance); carbidopa inhibits peripheral DOPA decarboxylase, increasing CNS delivery of levodopa and reducing peripheral dopaminergic effects (nausea, orthostatic hypotension) — it does not cross the blood–brain barrier. Dopamine agonists (pramipexole) and MAO-B inhibitors (rasagiline) are alternatives in younger patients to delay motor complications.
• Alzheimer disease — cholinesterase inhibitors (donepezil) counter nucleus basalis of Meynert cholinergic loss; the NMDA antagonist memantine is added in moderate-to-severe disease to blunt excitotoxicity (AAN/APA dementia guidance).
• Lewy body dementia: rivastigmine — cholinergic deficit is even more severe than in Alzheimer disease.
• ALS — anti-glutamatergic therapy: riluzole (inhibits glutamate release) modestly prolongs survival; edaravone, a free-radical scavenger, is FDA-approved.
• Huntington chorea — VMAT2 inhibitors (tetrabenazine, deutetrabenazine), per AAN guidance on chorea; antipsychotics are used when psychosis coexists.

Escalation and definitive management

• Anti-amyloid monoclonal antibodies (lecanemab, donanemab) are FDA-approved for biomarker-confirmed early Alzheimer disease; appropriate-use recommendations require amyloid confirmation and MRI monitoring.
• Deep brain stimulation of the subthalamic nucleus or globus pallidus interna for levodopa-responsive Parkinson disease with disabling motor fluctuations or dyskinesia; levodopa responsiveness predicts benefit.
• Multidisciplinary care (physical/speech therapy, palliative care, advance directives): multidisciplinary clinic care improves survival in ALS, and improves quality of life, function, and caregiver outcomes across the other neurodegenerative disorders.

Contraindicated / avoid

• Typical and most atypical antipsychotics in Lewy body dementia — severe neuroleptic sensitivity; use pimavanserin or quetiapine/clozapine cautiously. All antipsychotics carry an FDA boxed warning for increased mortality in elderly dementia patients.
• Anticholinergics (diphenhydramine, oxybutynin) worsen cognition (AGS Beers criteria); dopamine blockers (metoclopramide, haloperidol) worsen parkinsonism; abrupt levodopa withdrawal is hazardous.

Complications of the disease

• Aspiration pneumonia: bulbar motor neuron or corticobulbar degeneration produces dysphagia; signalled by wet voice, coughing with meals, and a new lower-lobe infiltrate. It is the leading terminal event in advanced Alzheimer disease and Parkinson disease. In ALS, by contrast, death results from neuromuscular respiratory failure due to diaphragmatic denervation, with aspiration pneumonia a frequent contributor.
• Neuromuscular respiratory failure (emergency): diaphragmatic denervation in ALS causes orthopnea, morning headache, and a falling vital capacity; hypercapnia precedes hypoxemia, so pulse oximetry is falsely reassuring.
• Falls, hip fracture, and subdural hematoma: loss of postural reflexes in Parkinson disease and progressive supranuclear palsy; brain atrophy stretches bridging veins, so a subdural may present as subacute confusion rather than trauma.
• Lobar intracerebral hemorrhage (emergency): from cerebral amyloid angiopathy — vascular Aβ weakens vessel walls; recurrent lobar bleeds and cortical microhemorrhages on gradient-echo/SWI MRI.
• Suicide and psychiatric decompensation: markedly increased in Huntington disease, both at genetic testing and with progression.
• Malnutrition, pressure ulcers, immobility, and venous thromboembolism in end-stage disease.

Complications of treatment

• Levodopa-induced dyskinesia and motor fluctuations: pulsatile stimulation of denervated striatal receptors; "wearing-off" and peak-dose choreiform movements after years of therapy.
• Impulse control disorders: pathologic gambling, hypersexuality, and compulsive shopping from dopamine agonists acting on mesolimbic D3 receptors — ask directly, patients rarely volunteer it.
• Parkinsonism-hyperpyrexia syndrome (emergency): abrupt levodopa withdrawal or pump failure produces rigidity, fever, autonomic instability, and elevated creatine kinase — a neuroleptic malignant-like state.
• ARIA (amyloid-related imaging abnormalities) with anti-amyloid monoclonal antibodies: vasogenic edema and microhemorrhage, more frequent in APOE4 carriers; symptomatic ARIA with headache, confusion, or seizure is an emergency requiring drug hold and MRI.
• Depression and suicidality with tetrabenazine (boxed warning) from monoamine depletion; parkinsonism is a dose-related effect.
• Cholinesterase inhibitors: bradycardia, syncope, GI cramping; antipsychotics in Lewy body dementia may precipitate life-threatening rigidity and autonomic collapse.
• DBS hardware complications: intracranial hemorrhage at electrode placement, infection, and stimulation-induced dysarthria or mood change.

• Match the protein to the disease: Aβ plaques plus hyperphosphorylated tau tangles = Alzheimer; alpha-synuclein = Parkinson/Lewy body dementia/multiple system atrophy; polyglutamine huntingtin = Huntington; TDP-43 = most ALS and the FTLD-TDP subtype. Tau is also the protein of Pick bodies, progressive supranuclear palsy, and corticobasal degeneration.
• **Congo red → *apple-green birefringence*** under polarized light is the classic amyloid buzzword; neuromelanin depigmentation of the substantia nigra and box-car (box-like) lateral ventricles from caudate atrophy are the gross-pathology equivalents for Parkinson and Huntington disease.
• The single association examiners test most: C9orf72 hexanucleotide repeat expansion is the most common genetic cause of both familial ALS and familial frontotemporal dementia — the same repeat links two clinical syndromes through TDP-43 pathology.
• Best next step in fluctuating cognition + early visual hallucinations + parkinsonism: recognize Lewy body dementia and withhold antipsychotics; giving haloperidol is the trap, and neuroleptic sensitivity can be fatal. Treat with a cholinesterase inhibitor.
• Timing rule (the "1-year rule"): dementia preceding or within a year of parkinsonism = dementia with Lewy bodies; dementia arising well after established Parkinson disease = Parkinson disease dementia. Pathology is identical.
• Huntington disease shows anticipation, with the largest CAG expansions in paternal transmission and juvenile-onset cases presenting with rigidity and seizures (Westphal variant), not chorea.
• ALS spares extraocular muscles, sphincters, and sensation; upper and lower motor neuron signs in the same limb with a normal sensory exam is the giveaway. Sensory involvement argues against ALS and should prompt evaluation for cervical spondylotic myelopathy or radiculopathy; MRI of the cervical spine is still required to exclude a compressive lesion even when the sensory exam is normal.
• Common distractor: before diagnosing degenerative dementia, exclude reversible mimics — B12 deficiency, hypothyroidism, neurosyphilis, and normal pressure hydrocephalus (gait apraxia, urinary incontinence, dementia with enlarged ventricles out of proportion to atrophy). Memantine is for moderate-to-severe Alzheimer disease, not mild cognitive impairment.